John Miller
Corporate Officer/Principal bei JAZZ PHARMACEUTICALS PLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bruce Cozadd | M | 60 | 21 Jahre | |
| Renée Galá | F | 52 | 4 Jahre | |
| Seamus Mulligan | M | 63 | 12 Jahre | |
| Mark Smith | M | 72 | 4 Jahre | |
| Anne O’Riordan | F | 56 | 5 Jahre | |
| Patricia Carr | F | 53 | 12 Jahre | |
| Norbert Riedel | M | 66 | 11 Jahre | |
| Catherine Sohn | M | 71 | 12 Jahre | |
| Jennifer Cook | F | 58 | 4 Jahre | |
| Heather McSharry | F | 62 | 11 Jahre | |
| Rick Winningham | M | 64 | 14 Jahre | |
| Ken O'Keefe | M | 57 | 20 Jahre | |
| Peter Gray | M | 69 | 11 Jahre | |
| Patrick Enright | M | 62 | 15 Jahre | |
| Robert Iannone | M | 57 | 5 Jahre | |
| Andrea N. Flynn | M | - | - | |
| Aislinn Doody | M | - | - | |
| Neena Patil | F | 49 | 5 Jahre | |
| Heidi Manna | F | 53 | 6 Jahre | |
| Shawn Mindus | M | - | - | |
| Kristin Bhavnani | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 Jahre |
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 Jahre |
| Ted Harding | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 2 Jahre |
| Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 Jahre |
| Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 Jahre |
| Mary Reumuth | F | 48 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 Jahre |
| Mittie Doyle | M | 59 | 3 Jahre | |
| Rebecca Velez Frey | F | - | 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Irland | 21 | 72,41% |
| Kanada | 6 | 20,69% |
| Vereinigte Staaten | 3 | 10,34% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Miller
- Persönliches Netzwerk
